In general, in cancer, the acquisition of drug resistance, which is commonly associated with treatment failures in cancer, may be lessened by combination therapies with different mechanisms of action, to include the vitamin K-mediated activation of PXR [32]. This evidence concerns the gene NR1I2 and cancer.